Clinical Trial Update: A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nivolumab for preventing recurrence of hepatocellular carcinoma after curative liver resection or ablation; the study is active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING